Inverness Medical Innovations is committed to researching and developing products in the hugely important area of cardiac risk.  Heart disease and stroke, the principal components of cardiovascular disease, are the first and third leading causes of mortality in the United States, accounting for more than 40 percent of all deaths.

Several traditional and new biomarkers are being recognized as important indicators of cardiac risk.  Inverness Medical offers both the Homocysteine and Macra Lp(a) ELISA tests, the Clearview Troponin I and Clearview D-dimer tests, and the breakthrough ACB® test to measure levels of Ischemia Modified Albumin as part of the growing cardiac test portfolio.

Please note that individual products may have different specifications in various markets.  Also, some products may not be available in all markets worldwide, only in selected markets.